A Point of Prostate Cancer Diagnosis Virtual Reality Assistant Intervention in Supporting Newly Diagnosed Black Men

Clinicaltrials.gov ID: NCT07126548
db-list-check Status RECRUITING
b-loader Phase NA
b-people Age All Ages
b-bullseye-arrow Enrollments 200

Conditions

Prostate Carcinoma

Summary

This clinical trial tests how well a point of prostate cancer diagnosis (PPCD) virtual reality assistant (ViRA) intervention works in supporting Black men with newly diagnosed prostate cancer. Cancer is the second leading cause of death for African American/Black men, with prostate cancer leading in estimated new cancer cases and second in estimated new cancer deaths. Over 40,000 African American/Black men are diagnosed with prostate cancer annually, with 1 in 6 lifetime probability of developing prostate cancer compared to 1 in 8 probability in White men. The PPCD ViRA provides psycho-oncology support, social determinants of health navigation and emotional support for ethnically diverse African American/Black men newly diagnosed with prostate cancer using artificial intelligence and augmented reality. Using PPCD ViRA may close the prostate cancer care gap for African American/Black men across the cancer continuum and provide emotional, educational, and resource needs of this population when they are visiting a doctor about their prostate health or prostate cancer.

Detailed Description

PRIMARY OBJECTIVES:

I. Evaluate the effectiveness of the PPCD ViRA (i) on the delivery of PPCD support in a clinic setting, at home and community setting; and (ii) in providing social determinants of health (SDOH) navigation, emotional support and psycho-oncology support for African American/Black men (AA/BM) newly diagnosed with prostate cancer (CaP).

II. Assess the effectiveness of the PPCD ViRA in reducing emotional distress and improving other patient reported outcomes (PROs).

III. Using a mixed-method approach, explore the factors that uniquely influence the implementation of the PPCD ViRA in a clinic setting, at home and community setting.

OUTLINE: Patients are randomized to 1 of 2 arms.

ARM I (DELAYED-START INTERVENTION): Patients receive standard care and then receive access to the ViRA application (app) (on a [virtual reality] VR headset, smartphone, iPAD or computer) and are presented with short screening questions, which an AI engine uses to recommend personalized and culturally tailored VR ready CaP interventions facilitated by a digital human character (CaP survivor, physician, or a psycho-oncologist) 3 months later on study.

ARM II (EARLY START INTERVENTION): Patients receive access to the ViRA app (on a VR headset, smartphone, iPAD or computer) and are presented with short screening questions, which an AI engine uses to recommend personalized and culturally tailored VR ready CaP interventions facilitated by a digital human character (CaP survivor, physician, or a psycho-oncologist) on study.

After completion of study intervention, patients are followed up at 1, 3, 6, 9 and 12 months.

Locations

1 location Found with status Recruiting

Status

  • RECRUITING

Contact Person

Principal Investigator

  • Folakemi T. Odedina, PhD

Eligibility Criteria

Inclusion Criteria:

* African American/Black male
* Diagnosed with CaP within two months
* Be a patient at a participating clinic or affiliates with one of our community sites
* Consent to participating in the study

Exclusion Criteria:

* Do not speak or understand English
* Unable to read or write

Study Plan

Arm I (delayed-start intervention [ViRA application])

EXPERIMENTAL

Patients receive standard care and then receive access to the ViRA app (on a VR headset, smartphone, iPAD or computer) and are presented with short screening questions, which an AI engine uses to recommend personalized and culturally tailored VR ready CaP interventions facilitated by a digital human character (CaP survivor, physician, or a psycho-oncologist) 3 months later on study.

  • OTHER:

    Best Practice

    Description:

    Receive standard care
  • OTHER:

    Discussion

    Description:

    Ancillary studies
  • OTHER:

    Survey Administration

    Description:

    Ancillary studies
  • PROCEDURE:

    Virtual Reality

    Description:

    Receive access to ViRA application

Arm II (ViRA application)

EXPERIMENTAL

Patients receive access to the ViRA app (on a VR headset, smartphone, iPAD or computer) and are presented with short screening questions, which an AI engine uses to recommend personalized and culturally tailored VR ready CaP interventions facilitated by a digital human character (CaP survivor, physician, or a psycho-oncologist) on study.

  • OTHER:

    Discussion

    Description:

    Ancillary studies
  • OTHER:

    Survey Administration

    Description:

    Ancillary studies
  • PROCEDURE:

    Virtual Reality

    Description:

    Receive access to ViRA application

Outcome Measures

Primary Outcome Measures

Reach - enrollment

Time Frame: Baseline

Reach - acceptance of ViRA

Time Frame: Baseline

Reach - initiation of ViRA

Time Frame: Baseline, 1 month, 3 months, 6 months, 9 months, 12 months

Utilization of the PPCD ViRA

Time Frame: Baseline, 1 month, 3 months, 6 months, 9 months, 12 months

Secondary Outcome Measures

Change in social determinants of health (SDOH) navigation

Time Frame: Baseline, 1 month, 3 months, 6 months, 9 months, 12 months

Change in emotional support

Time Frame: Baseline, 1 month, 3 months, 6 months, 9 months, 12 months

Psycho-oncology support

Time Frame: Baseline, 1 month, 3 months, 6 months, 9 months, 12 months

Timeline

  • Last Updated
    September 25, 2026
  • Start Date
    August 17, 2025
  • Today
    October 1, 2026
  • Completion Date ( Estimated )
    September 2, 2029

Similar Trials

light-list-check RECRUITING light-blue-people ≥ 18 Years
light-list-check RECRUITING light-blue-people ≥ 18 Years
light-list-check RECRUITING light-blue-people ≥ 18 Years